Dr. Adrienne Hammill developed an interest in genetic conditions associated with cancer prior to college. During hematology-oncology fellowship training, clinical experience caring for patients with known cancer predispositions involving PTEN and vascular malformations expanded this interest to include genetic conditions causing vascular tumors and vascular malformations.

This led to joining the Hemangioma and Vascular Malformations Center (HVMC) at Cincinnati Children's Hospital Medical Center as part of a distinguished multidisciplinary team focused on the care of patients with vascular anomalies.

As the understanding of the genetic basis of vascular anomalies rapidly evolved, Dr. Hammill worked to develop and direct specialized clinical programs, helping achieve designation as both a Sturge-Weber Clinical Care Network Center of Excellence and a Hereditary Hemorrhagic Telangiectasia (HHT) Center of Excellence.

Dr. Hammill currently serves as Research Director of HVMC and as site Principal Investigator for multiple industry-sponsored clinical trials focused on targeted therapies for vascular anomalies.

Through ongoing collaboration with basic scientists, clinical colleagues across the United States and internationally, and pharmaceutical partners, Dr. Hammill continues to advance the identification and development of new therapeutic approaches for patients with vascular anomalies.

She has also been an active participant in the Brain Vascular Malformations Consortium, contributing to both the Sturge-Weber syndrome program and the HHT program within the Rare Diseases Clinical Research Network.

Dr. Hammill is recognized as a leader in the treatment of vascular anomalies, with a strong focus on translating advances in genetic and molecular discovery into clinical care.